[高血压、肾素-血管紧张素-醛固酮系统阻断与新冠病毒感染患者的风险]
[Hypertension, RAAS blockade and risk in COVID-19 patients].
作者信息
Spaak Jonas, Kahan Thomas
机构信息
docent, bitr överläkare, ordförande i Svensk förening för hypertoni, stroke och vaskulär medicin, hjärtkliniken, Danderyds sjukhus.
professor, överläkare, hjärtkliniken, Danderyds sjukhus.
出版信息
Lakartidningen. 2020 Jun 23;117:20102.
SARS-coronavirus 2 (SARS-CoV-2) enters the host-cells by binding the transmembraneous angiotensin converting enzyme 2 (ACE2) when causing coronavirus disease 2019 (COVID-19). The role of angiotensin converting enzyme inhibitors (ACE) and angiotensin II receptor blockers (ARB) in COVID-19 is debated. Several well-conducted observational studies show no increased risk from RAAS blockade in COVID-19 patients and are detailed in this brief review. The Swedish Society of Hypertension, Stroke and Vascular Medicine supports current recommendations that ongoing RAAS blockade should be maintained in patients with COVID-19.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在引发2019冠状病毒病（COVID-19）时，通过与跨膜血管紧张素转换酶2（ACE2）结合进入宿主细胞。血管紧张素转换酶抑制剂（ACE）和血管紧张素II受体阻滞剂（ARB）在COVID-19中的作用存在争议。几项精心开展的观察性研究表明，COVID-19患者使用肾素-血管紧张素-醛固酮系统（RAAS）阻滞剂不会增加风险，本简要综述对此进行了详细阐述。瑞典高血压、中风和血管医学协会支持当前的建议，即COVID-19患者应继续维持RAAS阻滞剂治疗。
Zotero 插件